You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

153 Results
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's High Grade, 
Lymphoma - Non-Hodgkin's Intermediate Grade
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Epcoritamab (Outpatient) - Relapsed or Refractory Diffuse Large B-Cell Lymphoma
High Cost Therapy Funding Program
    Epcoritamab (Inpatient) - Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
epcoritamab
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Nov 2024
Guidelines and Advice
Status: Current
Version: PET 2023-2
Jun 2024
Document
Jul 2024
Document
Jul 2024
Regimen
Cancer Type:
Genitourinary, 
Bladder / Urothelial
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Drugs Used:
enfortumab vedotin (Compassionate),
pembrolizumab (Unfunded)
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Oct 2024
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Drugs Used:
elranatamab (Compassionate)
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Dec 2024
Drug
Other Name(s): Padcev®
Quick Link(s): Drug Monograph, Patient Info Sheet
Jan 2025
Regimen
Cancer Type:
Genitourinary, 
Bladder / Urothelial
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Enfortumab Vedotin - Previously Treated Advanced or Metastatic Urothelial Cancer
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
enfortumab vedotin
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jan 2025
Drug
Other Name(s): Epkinly™
Quick Link(s): Drug Monograph, Patient Info Sheet
Jan 2025
Guidelines and Advice
Status: Current
Version: 1
Nov 2024
Guidelines and Advice
Status: Current
ID: PET 2024-1
Updated
Mar 2025
Document
New
Apr 2025

Pages